Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
about
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancerChemotherapy and radiotherapy for inoperable advanced pancreatic cancerRecent progress in pancreatic cancerEmerging concepts in pancreatic cancer medicine: targeting the tumor stromaCurcumin AntiCancer Studies in Pancreatic CancerChemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysisNanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecanLocal Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A ReviewCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansPerspectives in the treatment of pancreatic adenocarcinomaAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsManagement of borderline and locally advanced pancreatic cancer: where do we stand?Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesSystemic treatment for inoperable pancreatic adenocarcinoma: review and updateInterplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesisSystemic therapies for pancreatic cancer--the role of pharmacogeneticsPancreatic cancer treatment and research: an international expert panel discussion.Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic CancerThe Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear StructureActivator protein 1 promotes gemcitabine‑induced apoptosis in pancreatic cancer by upregulating its downstream target BimGemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysisPredictive modeling of in vivo response to gemcitabine in pancreatic cancerIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineMeta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II studyPhase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic CancerDoes gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.Intravenous ω-3 Fatty Acids Plus Gemcitabine.
P2860
Q24240739-22280147-F322-491A-8BCF-FDADD595CBD9Q24245085-908F04E5-50AD-41F3-9A49-64AFBCB7ED79Q24626346-F2100857-2555-4E43-9D54-C75EF979DEA8Q24627664-66FA63F5-8446-49C9-BB24-29B1116A21E4Q26738714-C2E5310A-8C9A-475C-8F51-651FC6E8C1C1Q26746031-6B34DC51-E8FE-41DF-A684-B1937248CB24Q26747108-49559DF2-BC0F-4BFA-A05C-D1D8DD2EB3A8Q26751368-BF9D521F-3D83-4707-B13C-3B7250B12178Q26765288-72D08D63-8B6D-4A0E-8CD6-CDA52DA6B185Q26767041-5576F050-5945-4E03-9C38-20C108A08C8BQ26797248-85B9D49A-1704-4577-B07B-ED21EB0B7B78Q26798674-2A28567B-1D5E-4FF7-8E27-C116F9F19D70Q26825414-2D3149EC-F2C6-4B8F-A25F-AB498DA8B20FQ26828959-97C8146D-8F77-4DCF-85AA-177D16D011FBQ26830913-D9C0E364-B4BF-4484-9A25-6B516F09A93FQ26996794-068E99E7-6D35-4D31-BC97-8D3A778E83A8Q27021716-638A9409-E283-4E28-B1C6-9F961867FDC5Q27690868-3937897D-9D6E-4B20-939A-5AEDFCD94976Q28072210-8A9B1A89-8BF1-4A4B-B6E4-CBCB0CBF7D0AQ28084785-F74B67D9-383E-463F-8B4A-757BE1A157F0Q28468378-16E0D920-9E96-4427-A3D4-14A0825D3E90Q28487656-75A69172-3858-4A5B-B64D-61F6963E5043Q28533633-71EAEDE1-276A-4B76-B2B7-223964AE37FBQ29616728-407752E5-3567-4A9A-81C0-3598E250C285Q33326148-1CB10596-513E-4E76-93F2-4C1BF8AAA98CQ33350085-6F6E7A57-B307-49B8-9E4E-10710762A498Q33367733-DB79FD2C-95E5-4411-9C21-8B1CC13F0041Q33370390-2DFE0C10-75D1-476D-A87F-2ADE451F4DE1Q33371000-7EF2B112-A002-469A-82D0-88EE0B7B9D96Q33380084-2829B189-4C04-482B-B5EA-492485A401D6Q33382236-DF4C4617-BBEE-406E-A58B-1CA6F132C36AQ33384793-6A73DE1C-3F56-46C5-92FF-48C8B71188B0Q33387673-ADB442F9-8227-4763-B93C-5B6B67289D08Q33388392-8DF620FC-2F25-43E2-B1AB-8A61D32D07C6Q33394505-3DFD76CB-ECCC-4BAC-8C49-BC605C2B7C4CQ33395417-216D030D-A67B-44C1-A630-D4798874E8CBQ33402374-D1EA4B99-5A4F-433F-A664-D3AFD0DB18FCQ33403498-ECD2604A-154B-4E4D-A345-A041AB92B6B3Q33418870-B2362198-0FE3-4336-B0E1-9FA921CEBA98Q33424793-C867C04D-093D-4D5B-8706-E342E83BAAFE
P2860
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@ast
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@en
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@nl
type
label
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@ast
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@en
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@nl
prefLabel
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@ast
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@en
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@nl
P2093
P356
P1476
Irinotecan plus gemcitabine re ...... increased tumor response rate.
@en
P2093
Adele Morganti
Caio M Rocha Lima
G Mark Jeffrey
Gabriela Gruia
Langdon L Miller
Laura A Cisar
Mark R Green
Nicoletta Orlando
Robert Rotche
Wilson H Miller
P304
P356
10.1200/JCO.2004.12.082
P407
P577
2004-09-01T00:00:00Z